Literature DB >> 32282871

Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19).

Yulin Zhang1, Yuxue Gao1, Luxin Qiao1, Wenjing Wang1, Dexi Chen1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32282871      PMCID: PMC7175423          DOI: 10.7326/L20-0227

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
Background: A previous report of lung biopsies from a patient with coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) identified mononuclear cell infiltration but not the type of mononuclear cells (1). Objective: To describe the type of immune cells identified by imaging mass cytometry in lung tissue from 2 patients with COVID-19 and fatal ARDS. Case Reports: The first patient was a 94-year-old woman who had close contact with a confirmed case of COVID-19 eleven days earlier. She presented with an 8-day history of lethargy and fever (maximum temperature, 39 °C), and her history included 10 years of coronary heart disease. Physical examination found wheezing in both lungs and peripheral edema, and chest radiography identified right pulmonary infiltration and consolidation with right pleural effusion. She had a C-reactive protein level of 115.1 mg/L (normal level, <3 mg/L) and leukocyte count of 10.2 × 109 cells/L with 9% lymphocytes. Tests processed by the Beijing Centers for Disease Control confirmed that she had COVID-19. At the direction of her relatives, we provided noninvasive therapy that included supplemental oxygen and symptomatic treatment. She gradually developed dyspnea and hypoxemia and had a fatal cardiac arrest on day 10 of the illness. The second patient was a 65-year-old man whose wife had COVID-19. He presented with a 4-day history of dry cough, anorexia, and fever (maximum temperature, 38.6 °C). On admission, computed tomography of the chest showed bilateral pneumonia. He had a C-reactive protein level of 13.5 mg/L and a leukocyte count of 3.0 × 109 cells/L with 27.4% lymphocytes. Tests processed by the Beijing Centers for Disease Control confirmed that he had COVID-19. We initiated supportive therapy and administered moxifloxacin to prevent secondary infection. On day 15 of the illness, he required invasive ventilatory support. We changed his antibiotics to vancomycin and imipenem for suspected sepsis and administered intravenous methylprednisolone and immune globulin to attenuate systemic inflammation. On day 16, he had a C-reactive protein level of 244.4 mg/L, leukocyte count of 10.1 × 109 cells/L with 1.6% lymphocytes, and blood lactic acid level of 3.13 mmol/L. He developed septic shock and died on day 21 of the illness. Lung tissue was obtained by autopsy in both patients and by percutaneous biopsy in a control patient, a 54-year-old man with a pulmonary nodule. When we examined tissues stained with hematoxylineosin, the first patient had the typical histologic features of ARDS, with diffuse alveolar damage, alveolar septum edema, epithelial cell proliferation, hyaline membrane formation, infiltration of lymphocytes and monocytes into interstitial and alveolar spaces, and a small number of neutrophils. The second patient had the typical histologic features of bacterial pneumonia, with alveolar damage; alveolar septum edema; epithelial cell proliferation; and desquamation of pneumocytes, cellular fibromyxoid exudates, many phagocytes, neutrophil debris, and pus cells in alveolar cavities. The control patient had infiltration of interstitial inflammatory cells. Imaging mass cytometry on lung tissue from the first patient (Figure) found diffuse infiltration of CD4 T lymphocytes, macrophages (CD68), and a focal infiltration of natural killer cells (CD16 and CD107A). Tissue from the second patient had a cluster infiltration of neutrophils (CD11b and CD16) and activated macrophages (Arg1), a diffuse infiltration of mature T cells (CD45RA and CD4), and a scattered infiltration of natural killer cells and dendritic cells (CD276 and CD14), which distributed differently from macrophages and were accompanied by local overexpression of type 1 collagen. The distributions of infiltration by macrophages, mature T cells, and natural killer cells in the 2 patients were different, as was the expression of type 1 collagen, and the second patient had more dendritic cells. Both patients had relatively independent distributions of cell subsets by t-distributed stochastic neighbor embedding and PhenoGraph analysis. The first patient had more infiltration by immune cells. This patient had a cluster distribution of mature T cells (CD45RA) and macrophages. The second patient had a cluster distribution of mature T cells (CD45RA and CD45RO) and macrophages, which correlated with bacterial infection. More CD45RA+ T cells were recruited in the first patient, whereas mostly CD45RO+ T cells were recruited in the second patient. Additional data and figures are available from the authors on request.
Figure.

Imaging mass cytometry with markers of interest.

Representative mass cytometry images for each panel are different colors, and expression levels are in parentheses. Iridium-DNA staining is shown in blue. All images are from the same tissue sections. We designed a metal isotope–labeled antibody panel to detect multiple markers simultaneously in 1 slide by using the imaging mass cytometry system. For detailed methods, please refer to the Imaging Mass Cytometry Staining Protocol for FFPE Sections on the Fluidigm website (http://cn.fluidigm.com/search?query=IMC+Staining+Protocol&resourceTypes=protocol). All raw data were acquired using a Hyperion Imaging System (Fluidigm). The resulting files were in MCD format and were exported as TIFF files using the MCD Viewer. FFPE = formalin-fixed paraffin-embedded.

Imaging mass cytometry with markers of interest. Representative mass cytometry images for each panel are different colors, and expression levels are in parentheses. Iridium-DNA staining is shown in blue. All images are from the same tissue sections. We designed a metal isotope–labeled antibody panel to detect multiple markers simultaneously in 1 slide by using the imaging mass cytometry system. For detailed methods, please refer to the Imaging Mass Cytometry Staining Protocol for FFPE Sections on the Fluidigm website (http://cn.fluidigm.com/search?query=IMC+Staining+Protocol&resourceTypes=protocol). All raw data were acquired using a Hyperion Imaging System (Fluidigm). The resulting files were in MCD format and were exported as TIFF files using the MCD Viewer. FFPE = formalin-fixed paraffin-embedded. Discussion: Two previous studies of lung tissue from patients with severe acute respiratory syndrome found mononuclear cell infiltration and hyaline membrane formation (2, 3), whereas 1 previous study of a patient with COVID-19 and ARDS found interstitial infiltration by mononuclear cells (1). Our study suggests that these infiltrated mononuclear cells are CD4 T cells, CD8 T cells, natural killer cells, and macrophages; that recruitment of aberrant CD45RA+ T cells is the immunologic feature of COVID-19; and that once bacterial pneumonia occurs, some phagocytes recruited by CD4 T cells begin to play a major role in lung injury. We conclude that additional studies are needed to understand the immune response in patients with COVID-19.
  3 in total

1.  Lung pathology of fatal severe acute respiratory syndrome.

Authors:  John M Nicholls; Leo L M Poon; Kam C Lee; Wai F Ng; Sik T Lai; Chung Y Leung; Chung M Chu; Pak K Hui; Kong L Mak; Wilina Lim; Kin W Yan; Kwok H Chan; Ngai C Tsang; Yi Guan; Kwok Y Yuen; J S Malik Peiris
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

2.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China.

Authors:  Yanqing Ding; Huijun Wang; Hong Shen; Zhuguo Li; Jian Geng; Huixia Han; Junjie Cai; Xin Li; Wei Kang; Desheng Weng; Yaodan Lu; Dehua Wu; Li He; Kaitai Yao
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

3.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

  3 in total
  18 in total

1.  Presentation and Outcomes of Patients with ESKD and COVID-19.

Authors:  Anthony M Valeri; Shelief Y Robbins-Juarez; Jacob S Stevens; Wooin Ahn; Maya K Rao; Jai Radhakrishnan; Ali G Gharavi; Sumit Mohan; S Ali Husain
Journal:  J Am Soc Nephrol       Date:  2020-05-28       Impact factor: 10.121

Review 2.  The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.

Authors:  Lauren A Callender; Michelle Curran; Stephanie M Bates; Maelle Mairesse; Julia Weigandt; Catherine J Betts
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

3.  Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.

Authors:  Emanuele Pontali; Stefano Volpi; Giancarlo Antonucci; Marco Castellaneta; Davide Buzzi; Francesca Tricerri; Alessia Angelelli; Roberta Caorsi; Marcello Feasi; Francesca Calautti; Elio Castagnola; Gian Andrea Rollandi; Angelo Ravelli; Giovanni Cassola; Marco Gattorno
Journal:  J Allergy Clin Immunol       Date:  2020-05-11       Impact factor: 10.793

4.  In defence of extrapolation but not improvisation in SARS-CoV-2 lung disease.

Authors:  Oleg Epelbaum; Irene Galperin
Journal:  Breathe (Sheff)       Date:  2020-06

5.  The histopathological features of the explanted lungs from an end-stage COVID-19 patient.

Authors:  Kai Li; Youjia Yu; Ding Li; Changxing Luan; Li Hu; Jie Wang; Jingjing Ding; Yanfang Yu; Hang Yang; Jingyu Chen; Feng Chen; Chuan Su
Journal:  Forensic Sci Res       Date:  2020-09-01

6.  Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): a retrospective cohort study in a single medical centre.

Authors:  Xue Wang; Xincheng Li; Yu Shang; Junwei Wang; Xiaona Zhang; Dongju Su; Shuai Zhao; Qin Wang; Lei Liu; Yupeng Li; Hong Chen
Journal:  Epidemiol Infect       Date:  2020-09-09       Impact factor: 2.451

Review 7.  COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?

Authors:  Ritwick Mondal; Durjoy Lahiri; Shramana Deb; Deebya Bandyopadhyay; Gourav Shome; Sukanya Sarkar; Sudeb R Paria; Tirthankar Guha Thakurta; Pratibha Singla; Subhash C Biswas
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 5.221

Review 8.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Authors:  David Baker; Sandra Amor; Angray S Kang; Klaus Schmierer; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-05-12       Impact factor: 4.339

Review 9.  The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research.

Authors:  An Sen Tan; Sanjna Nilesh Nerurkar; Wei Chang Colin Tan; Denise Goh; Chi Peng Timothy Lai; Joe Poh Sheng Yeong
Journal:  SLAS Technol       Date:  2020-08-18       Impact factor: 3.047

10.  Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).

Authors:  Danielle Leão Cordeiro de Farias; João Prats; Alexandre Biasi Cavalcanti; Regis Goulart Rosa; Flávia Ribeiro Machado; Otávio Berwanger; Luciano César Pontes de Azevedo; Renato Delascio Lopes; Álvaro Avezum; Leticia Kawano-Dourado; Lucas Petri Damiani; Salomón Soriano Ordinola Rojas; Cleyton Zanardo de Oliveira; Luis Eduardo Coelho Andrade; Alex Freire Sandes; Maria Carolina Pintão; Claudio Galvão de Castro Júnior; Phillip Scheinberg; Viviane Cordeiro Veiga
Journal:  Rev Bras Ter Intensiva       Date:  2020 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.